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THE POPULATION COUNCIL:
PIONEERING NEW TOOLS TO PREVENT
HIV, STIS, AND UNINTENDED PREGNANCY
Population Council researchers are pioneering bold approaches to
reducing sexually transmitted infections (STIs) and unintended pregnancy
by developing a new generation of products, called multi-purpose
prevention technologies (MPTs). These MPTs—gels, fast-dissolving inserts, and intravaginal
rings—are designed to prevent HIV, other STIs, and/or unintended pregnancy simultaneously, allowing
women and men to lead healthy sexual and reproductive lives.
PC-1005 Gel

PC-9500 Fast-Dissolving Insert

PC-1005 gel is the only
candidate MPT designed for
both vaginal and rectal use
and to prevent HIV, HSV, and
HPV simultaneously. Based
on recent Phase 1 study data,
PC-1005 Is safe for vaginal use.
PC-1005 will undergo additional Phase 1 vaginal and
rectal testing in 2017-18.

The Population Council is
collaborating with PATH to develop
PC-9500, a candidate MPT designed
for on-demand vaginal, and possibly
rectal, use to prevent HIV, HSV,
and HPV simultaneously. PC-9500
contains a combination of griffithsin (GRFT) and
carrageenan, providing broad-spectrum antiviral
activity.

•

PC-1005 contains a combination of MIV-150, zinc
acetate, and carrageenan that provides broadspectrum antiviral activity.

•

GRFT is a naturally occurring algae-derived protein
that inhibits HIV and other pathogens, including
HSV.

•

MIV-150, a highly potent antiretroviral drug that is
effective against HIV.

•

GRFT is the most potent anti-HIV agent described
in the literature.

•

Zinc acetate, an antiviral that protects against HIV
and HSV.

•

GRFT could eliminate the risk of HIV drug crossresistance, because no other antiretroviral with
similar mode of action is used in treatment.

•

Carrageenan, a seaweed-derived compound with
highly potent activity against different types of
HPV. Carrageenan also strengthens zinc’s activity
against HSV.

•

When combined with carrageenan, GRFT also
inhibits HPV.

Innovative delivery systems for the drug
combinations in PC-1005 may include sustainedrelease intravaginal rings, or combining PC-1005
with a SILCS diaphragm.
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Intravaginal Ring
Council researchers are also
developing an IVR to provide
sustained-release protection from
HIV, HSV, and HPV for up to 90
days. FDI and IVR development will be supported by
a Phase 1 safety and PK study of a GRFT gel, which
is planned for 2017─18. This will be the first in-human
study of a GRFT MPT.

